New drug cocktail aims to shrink Hard-to-Treat tumors
Disease control
Not yet recruiting
This study tests a new drug called LM-168 combined with other cancer treatments (tislelizumab or docetaxel) in 108 adults with advanced solid tumors. The first part finds a safe dose; the second part checks if the combination shrinks tumors. It is not yet recruiting.
Phase: PHASE2 • Sponsor: LaNova Medicines Limited • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC